Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis
Open Access
- 23 October 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 11 (1) , 53-61
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeBone Marrow Transplantation, 2025
- Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2025
- Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cellsAutoimmunity Reviews, 2024
- Harnessing the potential of CAR-T cell in lupus treatment: From theory to practiceAutoimmunity Reviews, 2024
- Systemic lupus erythematosusThe Lancet, 2024
- KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITISKidney International, 2024
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- B-cell-targeted therapies in systemic lupus erythematosusCellular & Molecular Immunology, 2013
- B cell biomarkers of rituximab responses in systemic lupus erythematosusArthritis & Rheumatism, 2011